1. Home
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Drug Class, By Tumor Type, By Distribution Channel, By Region

Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Drug Class, By Tumor Type, By Distribution Channel, By Region

  • November 2022
  • 117 pages
  • ID: 6362625
  • Format: PDF
  • TechSci Research

Summary

Table of Contents

Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others), By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region

The global ovarian cancer drugs market is anticipated to witness an impressive growth during the forecast period, 2023-2027.Ovarian Cancer is one of the most severe and common cancer that affects the women these days.

The ovaries in this malignancy undergo irregular cell proliferation, which can invade or negatively impact other body parts like the liver, lymph nodes, intestine and bladder linings, abdominal layers, and lymph nodes.The early stages of ovarian cancer are accompanied by a few indistinct symptoms that become more obvious as the malignancy progresses.

These signs include bloating, pelvic pain, abdominal swell, and appetite loss.Ovarian Cancer risk is higher in women who have ovulated more frequently throughout their life, which can also include women who have never given birth and those who started ovulating at a young age.

According to the American Cancer Society estimations, the inherited genetic factors contribute to about 10% of occurrences of ovarian cancer. 50% of women who carry BRCA1 or BRCA2 gene mutations will get breast or ovarian cancer. The most frequent type of ovarian cancer, accounting for 95% of occurrences worldwide, is ovarian carcinoma.
Growing Prevalence of Ovarian Cancer
The market for ovarian cancer drugs is growing in a highly favourable environment due to the recent increase in ovarian cancer cases.The American Cancer Society reports that in 2016, there were approximately 22,280 new instances of ovarian cancer diagnosed, resulting in 14,240 fatalities in the United States.

Ovarian cancer accounted for 1.3% of the incidence rate and 2.4% of all fatalities attributable to cancer in 2016, according to statistics from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. There will be 23,820 new cases of ovarian cancer recorded in 2020, and the American Cancer Society believes that 1 in 75 women will get ovarian cancer during their lifetimes, with a 1 in 100 risks that she will pass away from it. As of 2017, 1,580 new ovarian cancer cases are anticipated to have been detected, making about 2.5% of all new cancer cases in the nation, according to the Australian Government’s Cancer Australia. 1,047 fatalities are anticipated because of this in 2017. Therefore, it is anticipated that the ovarian cancer drugs sector will soon experience significant growth in developed nations.
Increasing Elderly Female Population
The increase in the percentage of the elderly female population is expected to boost the global ovarian cancer drugs market during the forecast period.As the population of old females increases, they are projected to be suffering from more gynecological problems.

For instance, according to the World Population Prospects, there were about 9.5% females above the age group of 60 years as of 2021, from which most of the female population are susceptible to gynecological infections or diseases or cancer. Ovarian cancer prevalence is often low in women under the age of 40. Most of the ovarian cancer cases are observed among women 60 years of age and older, according to the American Cancer Society. 7,378 new cases of ovarian cancer were reported in the nation in 2014, with approximately 53% of those cases being identified in women 65 years of age and older, according to Cancer Research UK.

Increasing Research & Development Activities to Develop Ovarian Cancer Drugs
The growing prevalence of ovarian cancer has made the companies operating in the market along with different research organizations to increase their research & development activities in order to develop a potential drug treatment for ovarian cancer.Companies in the pharmaceutical business are increasingly coming up with novel drug combinations to treat ovarian cancer.

To treat complex medical diseases, combination medications combine two or more active pharmaceutical ingredients (APIs) into a single dosage form.To lower manufacturing costs, boost compliance and efficiency, enhance medication concordance, increase profitability, and lessen side effects, pharmaceutical companies in the ovarian cancer medications market are investing in the research and development of novel products such as combination drugs.

For instance, Roche’s well-known tranquilizer Avastin (bevacizumab), which is used to treat advanced stage (III or IV) ovarian cancer, is a combination drug approved by the FDA that contains ingredients like carboplatin and paclitaxel.
Market Segmentation
The global ovarian cancer drugs market is segmented into by drug class, by tumor type, by distribution, by region.Based on by drug class, the market can be fragmented into alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, antineoplastics and others.

Based on tumor type, the market can be categorized into epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor.Based on distribution channel, the market can be fragmented into hospital pharmacies, retail pharmacies, online pharmacies.

Regionally, North America dominated the market among Europe, Asia Pacific, Middle East & Africa and South America. The United States held the biggest market in North America region and is expected to be a lucrative market in the forecast period as the government is investing in research for new drugs for the easy detection of ovarian cancer for the affected people.

Market Players
AstraZeneca, Plc., GlaxoSmithKline, Plc., Merck & Co., Clovis Oncology, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn Ko. KG, Novartis AG are some of the leading players operating in the global ovarian cancer drugs market.

Report Scope:

In this report, global ovarian cancer drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Ovarian Cancer Drugs Market, By Drug Class:
o Alkylating Agents
o Mitotic Inhibitors
o Antirheumatics
o Antipsoriatics
o VEGF/VEGFR Inhibitors
o PARP Inhibitors
o Antineoplastics
o Others
• Ovarian Cancer Drugs Market, By Tumor Type:
o Epithelial Ovarian Cancer
o Ovarian Low Malignant Potential Tumor
o Germ Cell Tumor
o Sex Cord-Stromal Tumor
• Ovarian Cancer Drugs Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Ovarian Cancer Drugs Market, By Region:
o North America
United States
Canada
Mexico
o Europe
Germany
France
United Kingdom
Spain
Italy
o Asia Pacific
China
India
Japan
South Korea
Australia
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global ovarian cancer drugs market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Ovarian Cancer Drugs Market Research Report by Therapeutics Class, Modality, Drugs, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • $ 3949
  • January 2023
  • 243 pages

Ovarian Cancer Drugs Market Research Report by Therapeutics Class (Angiogenesis Inhibitors, PARP Inhibitors, and PD-L1 Inhibitors), Modality, Drugs, Region - Cumulative Impact of COVID-19, Russia Ukraine ...

  • World
  • Ovarian Cancer
  • Industry analysis

Global Alpha Emitters Industry $ 4950 January 2023


ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on